Drug Price Transparency
Medicare D prescription drug plan should not prevent pharmacies from telling customers when they could pay less for a drug by paying cash, the Centers for Medicare & Medicaid Services told plan sponsors yesterday.
The Food and Drug Administration today announced new efforts to spotlight situations where drugmakers may be pursuing “gaming tactics” to delay generic competition.
The Centers for Medicare & Medicaid Services today updated the Parts B and D drug spending dashboards with 2016 information.
The AHA Friday submitted comments to Sens. Bill Cassidy (R-LA), Michael Bennet (D-CO), Chuck Grassley (R-IA), Tom Carper (D-DE), Todd Young (R-IN) and Claire McCaskill (D-MO) as they develop legislation to improve price transparency in the health care market and lower costs.
The Campaign for Sustainable Rx Pricing released a digital and television ad urging Congress to pass the Creating and Restoring Equal Access to Equivalent Samples Act to lower drug prices.
Sens. Bill Cassidy (R-LA), Michael Bennet (D-CO), Chuck Grassley (R-IA), Tom Carper (D-DE), Todd Young (R-IN) and Claire McCaskill (D-MO) are seeking guidance from health care stakeholders as they develop legislation to improve price transparency in the health care market and lower costs.
WASHINGTON, DC (March 1, 2018) – Hospitals of all kinds provide a full range of benefits to their communities. In a new analysis released today, the American Hospital Associati
Letter to Congressional leaders from organizations to voice strong support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212) and encourage Congress to pass this important, bipartisan legislation as soon as possible.
While there has been recent high profile media coverage of retail drug price increases, the hospital inpatient pharmaceutical market is often overlooked and is not systematically evaluated. This report presents recent trends in hospital inpatient drug prices and spending, providing policymakers and…